Antisecretory medication is associated with decreased Helicobacter pylori detection in gastric marginal zone lymphoma

Kurt B. Schaberg, Mark F. Evans, Rebecca Wilcox, Michael R. Lewis

Research output: Contribution to journalArticle

Abstract

Helicobacter pylori status influences the prognosis and management of gastric extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma), so accurate determination of H pylori status is of clinical importance. The low rate of histologic H pylori positivity among gastric MALT lymphoma cases at our institution prompted investigation for possible causes. A case series of 24 patients as having gastric MALT lymphoma (with no diffuse large B-cell component) in a tertiary care setting between 1997 and 2010 was identified, and clinical records were reviewed. Immunohistochemical staining for H pylori and BCL10 was performed. This study received institutional review board approval (protocol number M13-033). Thirty-nine percent of cases (9/23) were H pylori positive by histology, and 4 additional patients had positive serologic results; overall, 57% of cases (13/23) were positive for H pylori. Treatment with antisecretory medications was associated with a lower likelihood of histologic positivity (13% among treated patients vs 75% among untreated; P =.04). Nuclear localization of BCL10 was seen in 2 cases and was not associated with H pylori status. Antisecretory medications decrease the likelihood of histologic detection of H pylori in gastric MALT lymphoma cases. Incorporation of results of serologic or other testing is needed to ensure correct classification with respect to H pylori status.

Original languageEnglish (US)
Pages (from-to)397-402
Number of pages6
JournalAnnals of Diagnostic Pathology
Volume19
Issue number6
DOIs
StatePublished - Dec 1 2015
Externally publishedYes

Fingerprint

Pylorus
Helicobacter pylori
Marginal Zone B-Cell Lymphoma
Lymphoma
Stomach
Research Ethics Committees
Tertiary Healthcare
Cellular Structures
Histology
B-Lymphocytes
Staining and Labeling

Keywords

  • Antisecretory medication
  • Gastric marginal zone lymphoma
  • Helicobacter pylori
  • Mucosa-associated lymphoid tissue

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Antisecretory medication is associated with decreased Helicobacter pylori detection in gastric marginal zone lymphoma. / Schaberg, Kurt B.; Evans, Mark F.; Wilcox, Rebecca; Lewis, Michael R.

In: Annals of Diagnostic Pathology, Vol. 19, No. 6, 01.12.2015, p. 397-402.

Research output: Contribution to journalArticle

@article{52cbdff3106c44b395e6ca80057acf4c,
title = "Antisecretory medication is associated with decreased Helicobacter pylori detection in gastric marginal zone lymphoma",
abstract = "Helicobacter pylori status influences the prognosis and management of gastric extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma), so accurate determination of H pylori status is of clinical importance. The low rate of histologic H pylori positivity among gastric MALT lymphoma cases at our institution prompted investigation for possible causes. A case series of 24 patients as having gastric MALT lymphoma (with no diffuse large B-cell component) in a tertiary care setting between 1997 and 2010 was identified, and clinical records were reviewed. Immunohistochemical staining for H pylori and BCL10 was performed. This study received institutional review board approval (protocol number M13-033). Thirty-nine percent of cases (9/23) were H pylori positive by histology, and 4 additional patients had positive serologic results; overall, 57{\%} of cases (13/23) were positive for H pylori. Treatment with antisecretory medications was associated with a lower likelihood of histologic positivity (13{\%} among treated patients vs 75{\%} among untreated; P =.04). Nuclear localization of BCL10 was seen in 2 cases and was not associated with H pylori status. Antisecretory medications decrease the likelihood of histologic detection of H pylori in gastric MALT lymphoma cases. Incorporation of results of serologic or other testing is needed to ensure correct classification with respect to H pylori status.",
keywords = "Antisecretory medication, Gastric marginal zone lymphoma, Helicobacter pylori, Mucosa-associated lymphoid tissue",
author = "Schaberg, {Kurt B.} and Evans, {Mark F.} and Rebecca Wilcox and Lewis, {Michael R.}",
year = "2015",
month = "12",
day = "1",
doi = "10.1016/j.anndiagpath.2015.10.001",
language = "English (US)",
volume = "19",
pages = "397--402",
journal = "Annals of Diagnostic Pathology",
issn = "1092-9134",
publisher = "W.B. Saunders Ltd",
number = "6",

}

TY - JOUR

T1 - Antisecretory medication is associated with decreased Helicobacter pylori detection in gastric marginal zone lymphoma

AU - Schaberg, Kurt B.

AU - Evans, Mark F.

AU - Wilcox, Rebecca

AU - Lewis, Michael R.

PY - 2015/12/1

Y1 - 2015/12/1

N2 - Helicobacter pylori status influences the prognosis and management of gastric extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma), so accurate determination of H pylori status is of clinical importance. The low rate of histologic H pylori positivity among gastric MALT lymphoma cases at our institution prompted investigation for possible causes. A case series of 24 patients as having gastric MALT lymphoma (with no diffuse large B-cell component) in a tertiary care setting between 1997 and 2010 was identified, and clinical records were reviewed. Immunohistochemical staining for H pylori and BCL10 was performed. This study received institutional review board approval (protocol number M13-033). Thirty-nine percent of cases (9/23) were H pylori positive by histology, and 4 additional patients had positive serologic results; overall, 57% of cases (13/23) were positive for H pylori. Treatment with antisecretory medications was associated with a lower likelihood of histologic positivity (13% among treated patients vs 75% among untreated; P =.04). Nuclear localization of BCL10 was seen in 2 cases and was not associated with H pylori status. Antisecretory medications decrease the likelihood of histologic detection of H pylori in gastric MALT lymphoma cases. Incorporation of results of serologic or other testing is needed to ensure correct classification with respect to H pylori status.

AB - Helicobacter pylori status influences the prognosis and management of gastric extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma), so accurate determination of H pylori status is of clinical importance. The low rate of histologic H pylori positivity among gastric MALT lymphoma cases at our institution prompted investigation for possible causes. A case series of 24 patients as having gastric MALT lymphoma (with no diffuse large B-cell component) in a tertiary care setting between 1997 and 2010 was identified, and clinical records were reviewed. Immunohistochemical staining for H pylori and BCL10 was performed. This study received institutional review board approval (protocol number M13-033). Thirty-nine percent of cases (9/23) were H pylori positive by histology, and 4 additional patients had positive serologic results; overall, 57% of cases (13/23) were positive for H pylori. Treatment with antisecretory medications was associated with a lower likelihood of histologic positivity (13% among treated patients vs 75% among untreated; P =.04). Nuclear localization of BCL10 was seen in 2 cases and was not associated with H pylori status. Antisecretory medications decrease the likelihood of histologic detection of H pylori in gastric MALT lymphoma cases. Incorporation of results of serologic or other testing is needed to ensure correct classification with respect to H pylori status.

KW - Antisecretory medication

KW - Gastric marginal zone lymphoma

KW - Helicobacter pylori

KW - Mucosa-associated lymphoid tissue

UR - http://www.scopus.com/inward/record.url?scp=84948390783&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84948390783&partnerID=8YFLogxK

U2 - 10.1016/j.anndiagpath.2015.10.001

DO - 10.1016/j.anndiagpath.2015.10.001

M3 - Article

C2 - 26615705

AN - SCOPUS:84948390783

VL - 19

SP - 397

EP - 402

JO - Annals of Diagnostic Pathology

JF - Annals of Diagnostic Pathology

SN - 1092-9134

IS - 6

ER -